Checkpoint Blockade + Chemotherapy: the Right Combination for AML?
暂无分享,去创建一个
[1] J. Serody,et al. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. , 2021, Blood cancer discovery.
[2] N. Daver,et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments , 2021, Leukemia.
[3] M. Konopleva,et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. , 2020, Blood advances.
[4] P. Sharma,et al. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study , 2019, Blood.
[5] D. Pe’er,et al. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies , 2019, Proceedings of the National Academy of Sciences of the United States of America.
[6] H. Kantarjian,et al. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2018, Blood.
[7] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[8] Matheus C. Bürger,et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.
[9] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[10] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.